SCYNEXIS to Participate in Upcoming January Investor Conferences

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

Presentation details:

• LifeSci Partners 11th Annual Corporate Access EventFormat: Virtual panel discussion with CEO and 1:1 meetingsPanel Title: The Best of Both Worlds – Defining Yourself When You Fit into More Than One BasketDate and Time: Friday, January 7, at 10:00 a.m. ETRegistration link: LifeSci Partners Corporate Access Event 2022

• H.C. Wainwright Bioconnect 2022 Virtual Healthcare ConferenceFormat: Virtual event with webcast of corporate update presentation by Dr. TagliettiDate and Time: Presentation webcast will be available on-demand January 10-13 for event participantsRegistration link: H.C. Wainwright Bioconnect 2022

The latest SCYNEXIS investor presentation can be found on the corporate website here.

About SCYNEXISSCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME® (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit www.brexafemme.com. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit www.scynexis.com. 

CONTACT: Investor RelationsIrina KofflerLifeSci AdvisorsTel: (646) 970-4681ikoffler@lifesciadvisors.com

Media RelationsGloria GasaaturaLifeSci CommunicationsTel: (646) 970-4688ggasaatura@lifescicomms.com